MARKET

SYRS

SYRS

Syros Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.33
+0.16
+2.16%
After Hours: 7.33 0 0.00% 16:30 02/20 EST
OPEN
7.11
PREV CLOSE
7.17
HIGH
7.47
LOW
7.02
VOLUME
108.17K
TURNOVER
--
52 WEEK HIGH
11.93
52 WEEK LOW
4.450
MARKET CAP
310.88M
P/E (TTM)
-3.7455
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SYRS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SYRS News

  • Syros Pharma Reports $60M Loan Facility With Oxford Finance
  • Benzinga.02/13 13:02
  • Syros Announces $60 Million Loan Facility with Oxford Finance LLC
  • Business Wire.02/13 13:00
  • Here's Why We're Watching Syros Pharmaceuticals's (NASDAQ:SYRS) Cash Burn Situation
  • Simply Wall St..02/06 19:03
  • Syros Presents New Preclinical Data Highlighting Its Leadership in CDK Inhibition to Discover and Develop New Medicines for Difficult-to-Treat Cancers
  • Business Wire.01/29 13:31

More

Industry

Pharmaceuticals
-0.54%
Pharmaceuticals & Medical Research
-0.40%

Hot Stocks

Name
Price
%Change

About SYRS

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
More

Webull offers Syros Pharmaceuticals Inc (SYRS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.